Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.52 |
| ▸ | CSNK1A1 | P48729 | 6/20 | 0.52 |
| ▸ | IKZF2 | Q9UKS7 | 4/20 | 0.50 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4457214 | 0.87 | CRBN (0.54) | CRBNCSNK1A1DDB1HDAC3HDAC1 | |
| SCHEMBL1413542 | 0.86 | CRBN (0.56) | CRBNCSNK1A1IKZF2DDB1NPC1 | |
| SCHEMBL4451283 | 0.86 | CRBN (0.53) | CRBNCSNK1A1DDB1HDAC3HDAC1 | |
| SCHEMBL1413838 | 0.85 | CRBN (0.62) | CRBNCSNK1A1IKZF2DDB1GSPT1 | |
| SCHEMBL23240143 | 0.85 | CRBN (0.56) | CRBNCSNK1A1IKZF2DDB1HDAC3 | |
| SCHEMBL4450646 | 0.85 | CRBN (0.54) | CRBNCSNK1A1IKZF2DDB1GSPT1 | |
| SCHEMBL1413390 | 0.83 | CRBN (0.59) | CRBNCSNK1A1IKZF2GSPT1 | |
| SCHEMBL1962542 | 0.83 | KMT2A (0.54) | CRBNCSNK1A1IKZF2DDB1HDAC3 | |
| SCHEMBL1413645 | 0.82 | CRBN (0.61) | CRBNCSNK1A1IKZF2DDB1GSPT1 | |
| SCHEMBL1413543 | 0.82 | CRBN (0.68) | CRBNCSNK1A1IKZF2DDB1GSPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3327013-B1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORP (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-3327013-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | Celgene Corporation (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-3061758-B1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORP (US) | 2018-01-31 | — | — | EP | disclosed |
| US-9801868-B2 | 5-substituted isoindoline compounds | CELGENE CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-20160346264-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2016-12-01 | — | — | US | disclosed |
| US-9447070-B2 | 5-substituted isoindoline compounds | CELGENE CORPORATION (US) | 2016-09-20 | — | — | US | disclosed |
| EP-3061758-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | Celgene Corporation (US) | 2016-08-31 | — | — | EP | disclosed |
| EP-2749559-B1 | 5-substituted isoindoline compounds | CELGENE CORP (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-2291365-B1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORP (US) | 2015-03-11 | — | — | EP | disclosed |
| US-20150005303-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2015-01-01 | — | — | US | disclosed |
| US-8877780-B2 | 5-substituted isoindoline compounds | CELGENE CORPORATION (US) | 2014-11-04 | — | — | US | disclosed |
| EP-2749559-A1 | 5-substituted isoindoline compounds | CELGENE CORPORATION (US) | 2014-07-02 | — | — | EP | disclosed |
| EP-2057143-B1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORP (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20090142297-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORPORATION | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346264-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CYP3A5, CYP3A7, CYP3A4 | CRBN 4610/4885CSNK1A1 554/4885IKZF2 3972/4885 |
| US-20150005303-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CYP3A5, CYP3A7, CYP3A4 | CRBN 4610/4885CSNK1A1 554/4885IKZF2 3972/4885 |
| US-20090142297-A1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CYP3A5, CYP3A7, CYP3A4 | CRBN 4610/4885CSNK1A1 554/4885IKZF2 3972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.